AU2006259307B2 - Epitope analogues - Google Patents

Epitope analogues Download PDF

Info

Publication number
AU2006259307B2
AU2006259307B2 AU2006259307A AU2006259307A AU2006259307B2 AU 2006259307 B2 AU2006259307 B2 AU 2006259307B2 AU 2006259307 A AU2006259307 A AU 2006259307A AU 2006259307 A AU2006259307 A AU 2006259307A AU 2006259307 B2 AU2006259307 B2 AU 2006259307B2
Authority
AU
Australia
Prior art keywords
peptide
analogs
nva
seq
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006259307A
Other languages
English (en)
Other versions
AU2006259307A1 (en
Inventor
Adrian Bot
David C. Diamond
Jian Gong
Liping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of AU2006259307A1 publication Critical patent/AU2006259307A1/en
Application granted granted Critical
Publication of AU2006259307B2 publication Critical patent/AU2006259307B2/en
Priority to AU2013201661A priority Critical patent/AU2013201661A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006259307A 2005-06-17 2006-06-16 Epitope analogues Ceased AU2006259307B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013201661A AU2013201661A1 (en) 2005-06-17 2013-03-19 Epitope Analogues

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69188905P 2005-06-17 2005-06-17
US60/691,889 2005-06-17
PCT/US2006/023489 WO2006138562A2 (en) 2005-06-17 2006-06-16 Epitope analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013201661A Division AU2013201661A1 (en) 2005-06-17 2013-03-19 Epitope Analogues

Publications (2)

Publication Number Publication Date
AU2006259307A1 AU2006259307A1 (en) 2006-12-28
AU2006259307B2 true AU2006259307B2 (en) 2012-12-20

Family

ID=37571207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006259307A Ceased AU2006259307B2 (en) 2005-06-17 2006-06-16 Epitope analogues

Country Status (12)

Country Link
US (5) US7511118B2 (enExample)
EP (4) EP2371851A3 (enExample)
JP (1) JP2008543314A (enExample)
KR (1) KR20080028938A (enExample)
CN (1) CN101273056A (enExample)
AU (1) AU2006259307B2 (enExample)
BR (1) BRPI0611793A2 (enExample)
CA (1) CA2612494A1 (enExample)
IL (2) IL188108A (enExample)
MX (1) MX2007015951A (enExample)
NZ (2) NZ590125A (enExample)
WO (1) WO2006138562A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP2385059A3 (en) 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US7511118B2 (en) * 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
NZ587601A (en) * 2005-06-17 2012-05-25 Mannkind Corp Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
EP3533461A3 (en) * 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
EP2152890A1 (en) * 2007-05-23 2010-02-17 MannKind Corporation Multicistronic vectors and methods for their design
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
EP2490713A2 (en) 2009-10-23 2012-08-29 MannKind Corporation Cancer immunotherapy and method of treatment
CA2781248A1 (en) * 2009-11-18 2011-05-26 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
US9345748B2 (en) * 2010-09-21 2016-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SSX-2 T cell receptors and related materials and methods of use
US9944675B2 (en) 2011-09-01 2018-04-17 University Of Southern California Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
US12374421B2 (en) * 2013-06-10 2025-07-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CN107266552B (zh) * 2016-03-30 2022-02-08 香雪生命科学技术（广东）有限公司 源自于prame的肿瘤抗原短肽
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US11814420B2 (en) 2018-07-06 2023-11-14 The Regents Of The University Of California Peptide deficient-MHC class I/chaperone compositions and methods
DK3817757T3 (da) * 2018-07-06 2026-03-09 Univ California Peptid-deficient mhc-klasse-i/chaperon-sammensætninger og fremgangsmåder
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
CN110950949B (zh) * 2018-09-26 2022-04-05 香雪生命科学技术（广东）有限公司 一种识别ssx2抗原的t细胞受体
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN112409474B (zh) * 2019-08-23 2023-02-28 香雪生命科学技术（广东）有限公司 一种识别ssx2抗原的高亲和力tcr
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021138688A1 (en) 2020-01-03 2021-07-08 The Regents Of The University Of California Systems and methods for identification of mhc-i peptide epitopes
US12534510B2 (en) 2020-04-16 2026-01-27 The Regents Of The University Of California Peptide-receptive MHC-I complex compositions and methods
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
AU2024334818A1 (en) * 2023-08-30 2026-03-19 Mink Therapeutics, Inc. Novel t cell receptors that bind to preferentially expressed antigen in melanoma (prame) and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081646A2 (en) * 2001-04-06 2002-10-17 Mannkind Corporation Epitope sequences
WO2006009920A2 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
WO2006014579A2 (en) * 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US590501A (en) 1897-09-21 Xxhixotoh
US2606601A (en) 1948-12-14 1952-08-12 Knoll Associates Chair having a back rest in the form of a shell-like body
JP2528457B2 (ja) * 1987-03-09 1996-08-28 サントリー株式会社 過酸化水素の定量法
US6417165B1 (en) * 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO2003040165A2 (en) * 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
EP1757695A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5747271A (en) * 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5935818A (en) 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6025191A (en) 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
EP1147212B1 (en) 1999-02-05 2009-08-26 The University Of Melbourne T helper cell epitopes
US6605711B1 (en) 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
JP2003524016A (ja) 2000-02-23 2003-08-12 エピミューン， インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの用途
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
BR0100425C2 (pt) 2001-01-12 2003-12-02 Daniel Villares Lenz Cesar Filtro autolimpante
WO2002069907A2 (en) 2001-03-07 2002-09-12 Mannkind Corporation Anti-neovasculature preparations for cancer
JP3830382B2 (ja) 2001-03-14 2006-10-04 日本碍子株式会社 セラミック焼結体およびその製造方法
US20030017134A1 (en) 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US7076244B2 (en) 2001-07-23 2006-07-11 Research In Motion Limited System and method for pushing information to a mobile device
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
EP1482963A4 (en) 2002-03-08 2010-06-09 Univ Texas CONTROLLED MODULATION OF THE AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGEN
WO2004005891A2 (en) * 2002-07-10 2004-01-15 The Regents Of The University Of Michigan Expression profile of lung cancer
US20040019571A1 (en) 2002-07-26 2004-01-29 Intel Corporation Mobile communication device with electronic token repository and method
AU2003261254A1 (en) 2002-07-31 2004-02-16 Ludwig Institute For Cancer Research Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
WO2004019968A1 (en) * 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
EP1545610A4 (en) * 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
US20050118186A1 (en) * 2003-06-17 2005-06-02 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
JP5127224B2 (ja) * 2003-06-17 2013-01-23 マンカインド コーポレイション 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US7511118B2 (en) * 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
EP2385059A3 (en) * 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
NZ587601A (en) * 2005-06-17 2012-05-25 Mannkind Corp Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
KR101718768B1 (ko) 2009-12-21 2017-03-22 삼성전자주식회사 휴대용 단말기에서 전력 소모를 줄이기 위한 장치 및 방법
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
US9814289B2 (en) 2015-04-08 2017-11-14 Otter Products, Llc Protective folio case for an electronic device
EP3636238B1 (en) 2018-10-12 2021-04-28 Liko Research & Development AB Gates with transition ramps for overhead lifting rails

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081646A2 (en) * 2001-04-06 2002-10-17 Mannkind Corporation Epitope sequences
WO2006009920A2 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
WO2006014579A2 (en) * 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KESSLER ET AL: J. Exp. Med, 2001, 193(1), 73-88 *

Also Published As

Publication number Publication date
US20130017213A1 (en) 2013-01-17
EP1896498B1 (en) 2014-12-24
IL188108A0 (en) 2008-03-20
WO2006138562A3 (en) 2007-07-26
EP2371850A3 (en) 2012-08-01
EP2371850A2 (en) 2011-10-05
EP2371852A3 (en) 2012-08-01
US20070060524A1 (en) 2007-03-15
CN101273056A (zh) 2008-09-24
IL188108A (en) 2015-03-31
IL209963A0 (en) 2011-02-28
MX2007015951A (es) 2008-03-07
JP2008543314A (ja) 2008-12-04
US7511118B2 (en) 2009-03-31
US20070060518A1 (en) 2007-03-15
EP2371851A3 (en) 2012-08-01
KR20080028938A (ko) 2008-04-02
AU2006259307A1 (en) 2006-12-28
US20100303842A1 (en) 2010-12-02
EP2371852A2 (en) 2011-10-05
NZ564359A (en) 2011-09-30
US20070049533A1 (en) 2007-03-01
US7511119B2 (en) 2009-03-31
NZ590125A (en) 2012-07-27
US7605227B2 (en) 2009-10-20
EP1896498A2 (en) 2008-03-12
EP2371851A2 (en) 2011-10-05
BRPI0611793A2 (pt) 2009-01-13
WO2006138562A2 (en) 2006-12-28
CA2612494A1 (en) 2006-12-28
US8653237B2 (en) 2014-02-18

Similar Documents

Publication Publication Date Title
AU2005265182B2 (en) Epitope analogs
US8653237B2 (en) Peptide analogues
CN101001868A (zh) 表位类似物
AU2013201661A1 (en) Epitope Analogues
HK1163116A (en) Epitope analogues
HK1163115A (en) Epitope analogues
HK1163117A (en) Epitope analogues
NZ583226A (en) Epitope analogs
HK1159124A (en) Epitope analogs
HK1122823A (en) Epitope analogues

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired